Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7411 to 7425 of 7707 results

  1. Housing: planning to improve health and wellbeing

    Discontinued [GID-NG10053]

    NICE guideline
    Discontinued

  2. Cediranib with olaparib for treating recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer after 3 therapies [ID1639]

    In development [GID-TA10607] Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Pancreatic cancer (metastatic) - nimotuzumab (1st line) [ID513]

    Discontinued [GID-TAG363]

    Technology appraisal guidance
    Discontinued

  4. Lapatinib for breast cancer (for use in women with previously treated advanced or metastatic breast cancer) [ID20]

    Discontinued [GID-TAG387]

    Technology appraisal guidance
    Discontinued

  5. Gastrointestinal stromal tumours (unresectable, metastatic) - masitinib (after progression with imatinib) [ID622]

    Discontinued [GID-TAG360]

    Technology appraisal guidance
    Discontinued

  6. Breast cancer (locally advanced or metastatic) - ixabepilone [ID377]

    Discontinued [GID-TAG403]

    Technology appraisal guidance
    Discontinued

  7. Prostate cancer (prevention) - dutasteride [ID75]

    Discontinued [GID-TAG409]

    Technology appraisal guidance
    Discontinued

  8. Atrial fibrillation - idraparinux sodium [ID375]

    Discontinued [GID-TAG383]

    Technology appraisal guidance
    Discontinued

  9. New pharmaceutical treatments for non-Alzheimer dementias [ID380]

    Discontinued [GID-TAG369]

    Technology appraisal guidance
    Discontinued

  10. Sunitinib in combination with capecitabine for the treatment of advanced and/or metastatic breast cancer [ID319]

    Discontinued [GID-TAG410]

    Technology appraisal guidance
    Discontinued

  11. Prasterone for the treatment of systemic lupus erythematosus [ID392]

    Discontinued [GID-TAG373]

    Technology appraisal guidance
    Discontinued

  12. Sunitinib in combination with a taxane for the first line treatment of advanced and/or metastatic breast cancer [ID58]

    Discontinued [GID-TAG391]

    Technology appraisal guidance
    Discontinued

  13. Masitinib for the treatment of locally advanced or metastatic pancreatic cancer [ID566]

    Discontinued [GID-TAG330]

    Technology appraisal guidance
    Discontinued

  14. Laquinimod for treating relapsing-remitting multiple sclerosis [ID560]

    Discontinued [GID-TAG337]

    Technology appraisal guidance
    Discontinued

  15. Cetuximab for the treatment of advanced non-small-cell lung cancer [ID9]

    Discontinued [GID-TAG395]

    Technology appraisal guidance
    Discontinued